Amgen, Inc. is hoping to be a competitive player in the red-hot obesity market despite being well behind frontrunners Novo Nordisk A/S and Eli Lilly and Company. The company is studying two drugs in clinical trials for obesity and has others in preclinical development.
Amgen’s Plan To Go Big In Obesity
Competing in the obesity market will require significant investment, which Amgen is preparing for, CEO Robert Bradway told investors during the Morgan Stanley Healthcare conference.